The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
June 19th 2025
Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.
Case Investigated of Patient With Possible COVID-19–Induced Myasthenia Gravis
August 2nd 2023Investigators conducted a case study of a patient who presented with COVID-19–induced seronegative myasthenia gravis, seeking more information on neurological manifestations of the respiratory disease.
Read More
Coverage of sessions on disparities in access to clinical trials and cancer screening, as well as relationships each to outcomes. A joint session presented by ASCO and the European Society for Medical Oncology (ESMO) highlighted progress and lingering gaps in lung and colorectal screening.
Read More
ASCO 2023: Leukemia and Lymphoma
July 31st 2023Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.
Read More
Side-Opening Cutting Forceps Safe, Reliable for Use in Pediatric EoE
July 31st 2023With data on side-opening cutting forceps showing above a 90% diagnostic rate for tissue biopsy in adult patients with eosinophilic esophagitis (EoE) who undergo biopsy of the esophageal lamina propia (ELP), investigators conducted a pilot study on use of side-opening cutting forceps in younger patients.
Read More
Study Finds Link Between Baseline Uric Acid Levels and Prostate Cancer Prognosis
July 31st 2023Researchers linking uric acid (UA) levels to the aggressiveness and progression of prostate cancer believe these findings can be used to study UA influence on prostate cancer–related mortality risk.
Read More
Amid Increasing Breast Implant–Related EBV+ DLBCL Cases, Researchers Share Insights on the Disease
July 31st 2023Recognition of the association between breast implants and lymphomas has been notable since the 1990s, although the association has been limited to breast implant–associated anaplastic large cell lymphoma and not Epstein-Barr virus (EBV).
Read More
Dr Haley Naik: Improved Medical Education Can Help Reduce Diagnostic Delays of HS
July 30th 2023Some populations face longer diagnostic delays for hidradenitis suppurativa (HS), but medical education can help improve knowledge of common dermatologic diseases and reduce delays in diagnosis, said Haley Naik, MD, FAAD, associate professor of dermatology, University of California, San Francisco, School of Medicine.
Watch
Group Highlights Barriers to CAR T-Cell Referral for DLBCL
July 29th 2023The researchers emphasized the importance of early referral for chimeric antigen receptor (CAR) T-cell treatment, as patients eligible for the treatment are often in very late stages of disease, and mitigating delays in care has the potential to improve response rates by more than 10%.
Read More
Overall Survival in Advanced NSCLC Unaffected by Immunotherapy Duration Beyond 2 Years
July 29th 2023Researchers seeking answers regarding the most beneficial duration of immune checkpoint inhibitor–based therapy for non–small cell lung cancer (NSCLC) found no significant impact of indefinite-duration treatment on patient survival.
Read More
Study Validates First Disease-Specific PRO Instrument for Patients With Congenital TTP
July 27th 2023Congenital thrombotic thrombocytopenic purpura (TTP), an ultra-rare disease, can significantly impact quality of life, but clinicians have previously lacked a disease-specific way to track experiences via patient-reported outcomes (PROs).
Read More